CZAR-1

Study Design: Phase II, randomized, multicenter, international trial

Patients: treatment naive and relapsed WM patients

Treatment: Carfilzomib/Ibrutinib versus Ibrutinib

Status of the Study: recruiting (first patient in Feb 2021, n= 99)

Sponsor: University Hospital of Ulm, PI Christian Buske